Mercedes
Garayoa Berrueta
Investigadora desde 2011
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (7)
2021
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications, Vol. 12, Núm. 1
2017
-
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care
Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines
PLoS ONE, Vol. 9, Núm. 3
-
Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease
Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554
2013
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Blood, Vol. 122, Núm. 22, pp. 3591-3598